猴菇和胃颗粒治疗胃癌前病变的临床疗效及对炎症因子与免疫功能的影响

Clinical Efficacy of Hougu Hewei Granules in the Treatment of Gastric Precancerous Lesions and the Effects on Inflammatory Factors and Immune Function

摘要

[目的 探讨猴菇和胃颗粒治疗胃癌前病变的临床疗效，以及对患者血清炎症因子与免疫功能的影响。方法 选取 2023 年 1 月至 2025 年 1 月广东省第二中医院收治的胃癌前病变患者 102 例，按照随机数字表法分为观察组与对照组，各 51 例。对照组口服胃复春片，观察组服用猴菇和胃颗粒，2 组的疗程均为 12 周。比较 2 组治疗 12 周后的总有效率；分别于治疗前、治疗 4 周和 12 周后，比较 2 组中医证候积分、炎症因子[白细胞介素-6 （interleukin-6，IL-6）、白细胞介素-8 （interleukin-8，IL-8）和肿瘤坏死因子-α （tumor necrosis factor-α，TNF-α）]水平、免疫功能指标（CD3⁺、CD4⁺和 CD4⁺/CD8⁺比值）变化；记录患者治疗期间不良反应发生情况。结果 观察组的治疗总有效率为 90.20%，高于对照组的 74.51% （P < 0.05）。2 组在治疗 4 周和 12 周后的胃痛、胃胀和痛处拒按积分、IL-6、IL-8 和 TNF-α 水平低于治疗前，CD3⁺、CD4⁺和 CD4⁺/CD8⁺比值高于治疗前（P < 0.05），且 2 组在治疗 12 周后的中医证候积分、炎症因子水平低于治疗 4 周后，免疫功能指标高于治疗 4 周后（ P < 0.05）；观察组在治疗 4 周和 12 周后的胃痛、胃胀和痛处拒按积分、IL-6、IL-8 和 TNF-α 水平低于对照组，CD3⁺、CD4⁺和 CD4⁺/CD8⁺高于对照组（P < 0.05）。治疗期间，2 组均未发生不良反应。结论 猴菇和胃颗粒对胃癌前病变患者的疗效显著，可有效改善患者中医证候，减轻机体炎症反应并调节免疫功能，具有临床应用价值。

Abstract

Objective To explore the clinical efficacy of Hougu Hewei Granules in the treatment of gastric precancerous lesions, and its effects on serum inflammatory factors and immune function in patients.Methods A total of 102 patients with gastric precancerous lesions admitted to Guangdong Second Traditional Chinese Medicine Hospital from January 2023 to January 2025 were enrolled and divided into an observation group and a control group by random number table method, with 51 cases in each group. The control group took Weifuchun Tablets orally, while the observation group took Hougu Hewei Granules orally. The course of treatment was 12 weeks for both groups. The total effective rate was compared between the two groups after 12 weeks of treatment. The changes of traditional Chinese medicine (TCM) syndrome scores, levels of inflammatory factors [interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor-α (TNF-α)] and immune function indicators (CD3⁺, CD4⁺and CD4⁺/CD8⁺ ratio) were compared between the two groups before treatment, after 4 weeks and 12 weeks of treatment. Adverse reactions during treatment were recorded in both groups.Results The total effective rate of the observation group was 90.20%, which was higher than that of the control group (74.51%) (P< 0.05). After 4 weeks and 12 weeks of treatment, the scores of stomach pain, bloating and pain aggravated by pressure, as well as the levels of IL-6, IL-8 and TNF- α in the two groups were lower than those before treatment, while the percentages of CD3⁺ and CD4⁺ , and the CD4⁺/CD8⁺ratio were higher than those before treatment (P< 0.05). The TCM syndrome scores and inflammatory factor levels of both groups after 12 weeks of treatment were lower than those after 4 weeks of treatment, and the immune function indicators were higher than those after 4 weeks of treatment (P< 0.05). After 4 weeks and 12 weeks of treatment, the scores of stomach pain, bloating and pain aggravated by pressure, and the levels of IL-6, IL-8 and TNF-α in the observation group were lower than those in the control group, while the percentages of CD3⁺and CD4⁺, and the CD4⁺/CD8⁺ ratio were higher than those in the control group (P< 0.05). No adverse reactions occurred in either group during the treatment period.Conclusion Hougu Hewei Granules has significant therapeutic effect on patients with gastric precancerous lesions. It can effectively improve TCM syndromes, alleviate inflammatory response and regulate immune function, with good value for clinical application and promotion.

关键词

猴菇和胃颗粒 / 胃癌前病变 / 临床疗效 / 炎症反应 / 作用机制

Key words

Hougu Hewei Granules / gastric precancerous lesions / clinical efficacy / inflammatory response / mechanism of action

参考文献

[1] Qing X U, Wang Y, Zhongyu L I,et al. Therapeutic mechanisms of integrated traditional Chinese and conventional medicine underlying its treatment of precancerous lesions of gastric cancer[J].J Tradit Chin Med, 2022, 42(6): 1023-1028.

[2] Cao T L, Jiang H Z. Gastrointestinal microbiota in treatment of gastric precancerous lesions and gastric cancer by Western and traditional Chinese medicine[J].World J Clin Oncol, 2025, 16(8): 107660.

[3] 张丹, 倪家慧, 张喜, 等. 健脾化瘀解毒方调控PKA/NLRP3通路治疗胃癌前病变的机制[J].中华中医药杂志, 2024, 39(9): 4605-4611.

[4] 王立业, 张艳彬, 朱亚楠, 等. 益胃解毒方联合复胃散胶囊治疗脾胃虚弱型幽门螺杆菌阳性胃癌前病变临床观察[J].北京中医药, 2025, 44(5): 566-570.

[5] 居凌云, 叶小峰, 李保良, 等. 百合乌药泻心汤合小六金健胃方对脾胃湿热证慢性萎缩性胃炎癌前病变患者的临床疗效[J].中成药, 2025, 47(2): 673-677.

[6] 贾业贵, 肖丹, 刘琼, 等. 胃复春抑制NF-κB/GSDME 介导的细胞焦亡治疗胃癌前病变[J].中国实验方剂学杂志, 2024, 30(21): 61-69.

[7] 中华医学会消化病学分会, 中华医学会消化病学分会消化系统肿瘤协作组. 中国慢性胃炎诊治指南(2022 年，上海)[J].中华消化杂志, 2023, 43(3): 145-175.

[8] 邹煜明. 胃肠安方治疗脾虚型胃癌前病变临床研究[J].上海中医药杂志, 2013, 47(12): 40-42.

[9] 黄柳向, 何凡应, 李玲. 黄芪莪术药对调控Akt/FoxO3a 信号通路对胃癌前病变的影响研究[J].现代中西医结合杂志, 2023, 32(13): 1767-1772, 1777.

[10] 荣华, 付永民, 杜旭. 丹石健脾汤联合针灸治疗慢性萎缩性胃炎胃癌前病变43例[J].环球中医药, 2023, 16(4): 765-768.

[11] 张志威, 宋梦蝶, 毛宇湘, 等. 化浊解毒通络方治疗胃癌前病变浊毒蕴胃证患者的疗效及作用机制研究[J].世界中医药, 2024, 19(20): 3137-3142.

[12] 李紫昕, 戈焰. 猴菇和胃颗粒治疗慢性萎缩性胃炎伴不同类型肠上皮化生的临床疗效[J].内蒙古中医药, 2022, 41(1): 3-4.

[13] 公艳霞, 白敏, 刘自由, 等. 基于IL-6/JAK2/STAT3 通路探讨化瘀消痞汤对胃癌前病变大鼠胃黏膜损伤的作用及机制[J].中药新药与临床药理, 2024, 35(12): 1827-1834.

[14] 代明龙, 张所山. 化瘀解毒通络方治疗胃络瘀毒型胃癌前病变疗效及对患者炎症因子、COX-2、PG I和G-17表达影响研究[J].四川中医, 2023, 41(1): 118-122.

基金资助

广州市科技计划项目(No. 202201011300)